Pediatric Solid Tumor Metabolism [A Prospective Study Exploring Metabolism of Solid Tumors in Pediatrics]

The University of Texas System (UT)

Status: Completed

Conditions: Sarcoma; Neuroblastoma; Pediatric Cancer

Treatments: Other: No glucose infusion; Drug: 13C-glucose

Study type: Observational

Funder types: Other

Identifiers

NCT03686566

STU 052018-100

Details and patient eligibility

About

To explore metabolic phenotypes of children with extra-cranial solid tumors and compare these with their histopathological and genetic alterations to discover potential novel biomarkers and therapeutic targets to improve outcomes in children with high risk disease.

Full description

The principal objective of this study is the metabolic characterization of pediatric solid tumors, with a particular focus on neuroblastoma (NBL) and fusion positive sarcoma (FPS), which will allow the detection of tumor specific metabolic alterations that can be exploited with the aim of developing novel therapeutic strategies and biomarkers.

Cellular metabolism studies provide insight, in a complementary way to genomics, into processes acting downstream from oncogenes and oncogenic fusion proteins, and such insight may point toward previously unrecognized therapeutic targets or onco-metabolites that are traceable as robust biomarkers for response. The investigator's new approach to use an in-vivo comprehensive analysis of metabolic reprograming in FPS/NBL has never been performed in childhood FPS/NBL and will complement genomics studies for these cancers. For this study, the investigators plan to obtain tumor samples at time of surgical biopsy/resection and study their metabolic signatures.

Enrollment: 84 patients

Sex: All

Ages: Under 26 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Suspected malignancy
• Age ≤ 26 years and being cared for at Children's Medical Center
• Ability to undergo standard of care diagnostic procedure, including biopsy or resection of the tumor, in the OR or IR at CMC

Exclusion criteria

• Poorly controlled diabetes
• Any other medical condition that prevents administration of glucose

Trial design

84 participants in 2 patient groups

13C-glucose infusion

Description:

Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.

Treatment:

Drug: 13C-glucose

No 13C-glucose infusion

Description:

Tumor samples of patients who do not choose to receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.

Treatment:

Other: No glucose infusion